Boston, MA (PressExposure) April 09, 2012 -- Dr. Meyers joined Alnylam in April of 2003 as Associate Director of Research, after having served as a Senior Scientist at Millennium Pharmaceuticals (1999-2003). At Millennium Pharmaceuticals, Dr. Meyers was involved in target advancement and the identification, bioinformatic analysis, cloning and functional analysis of novel targets for small molecule drug discovery, antibody development and diagnostic purposes. At Alnylam, Dr. Meyers oversees the RLD and immunology groups and plays a key role in the development of Alnylam's RNAi therapeutic programs. Dr. Meyers holds a degree in Biochemistry from Brandeis University and a Ph.D. in Biology from MIT, and she completed her post-doctoral training at Harvard Medical School. Dr. Meyers is a member of the advisory board for the MS program in Biotechnology at Brandeis University.
GTC's 3rd RNAi Research and Therapeutics conference is the only RNAi conference that brings together a balanced mix of over 25 leading experts from the industry and academia to collaborate on the latest cutting edge research on novel delivery methods, therapeutics, diagnostics, clinical applications, target discovery and validation in the RNAi field. Join us at the conference to hear from and meet with key representatives from the RNAi field such Craig C. Mello, John J. Rossi, the Head of RNA Optimization at Merck, the Vice President of Research and RLD at Alnylam, etc.
The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences. Register for the entire summit and have access to the all of the following conferences:
2nd Genomic & Proteomic Drug Discovery Conference
2nd Epigenetics in Drug Discovery Conference
7th Protein Kinases in Drug Discovery Conference
2nd Next Generation Sequencing Conference
Genome-wide Partnering and Deal Making Conference
Sign up for the pre-summit workshop on Clinical Sequencing on May 29th. This interactive workshop is dedicated to discussing emerging technologies, current and future trends of clinical sequencing, and the implementation of next generation sequencing in a CLIA environment.
For more information, please visit http://www.gtcbio.com